Boehringer Ingelheim Pharmaceuticals has agreed to buy the US rights to OTC Zantac from Johnson & Johnson and Pfizer Consumer Healthcare for US$510 million (€408 million) in cash.
The deal represents 3.8-times Zantac’s annual US sales of US$132 million. The heartburn remedy based on the H2-antagonist ranitidine is available in the US as Zantac 75 Acid Reducer and Maximum Strength Zantac 150 Acid Reducer.
No comments:
Post a Comment